CLINICAL_TRIALS
trial_result
· 2017-02-01
Clinical Trial Update: The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes [Phase 2]
Summary
Phase 2 trial results show the effect of ruboxistaurin (LY333531) on proteinuria in patients with diabetic nephropathy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chromaderm, Inc. | Conditions: Diabetic Nephropathy | Phase 2 | Status: COMPLETED